Prognostic value of early sustained ventricular arrhythmias in ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: A substudy of VALIDATE-SWEDEHEART trial
Research article published in Heart Rhythm O2 (2022)
Abstract
BACKGROUND: Prognostic assessment of ventricular tachycardia (VT) or ventricular fibrillation (VF) in ST-segment elevation myocardial infarction (STEMI) is based mainly on distinguishing between early (<48 hours) and late arrhythmias, and does not take into account its time distribution with regard to reperfusion, or type of arrhythmia. OBJECTIVE: We analyzed the prognostic value of early ventricular arrhythmias (VAs) in STEMI with regard to their type and timing. METHODS: The prespecified analysis of the multicenter prospective Bivalirudin versus Heparin in ST-Segment and Non-ST-Segment Elevation Myocardial Infarctionin Patients on Modern Antiplatelet Therapy in the Swedish Web System for Enhancement and Development of Evidence-based Care in Heart Disease evaluated according to Recommended Therapies Registry Trial included 2886 STEMI patients undergoing primary percutaneous coronary intervention (PCI). VA episodes were characterized regarding their type and timing. Survival status at 180 days was assessed through the population registry. RESULTS: Nonmonomorphic VT or VF was observed in 97 (3.4%) and monomorphic VT in 16 (0.5%) patients. Only 3 (2.7%) early VA episodes occurred after 24 hours from symptom onset. VA was associated with higher risk of death (hazard ratio 3.59; 95% confidence interval [CI] 2.01-6.42) after adjustment for age, sex, and STEMI localization. VA after PCI was associated with an increased mortality compared with VA before PCI (hazard ratio 6.68; 95% CI 2.90-15.41). Early VA was associated with in-hospital mortality (odds ratio 7.39; 95% CI 3.68-14.83) but not with long-term prognosis in patients discharged alive. The type of VA was not associated with mortality. CONCLUSION: VA after PCI was associated with an increased mortality compared with VA before PCI. Long-term prognosis did not differ between patients with monomorphic VT and nonmonomorphic VT or VF, but events were few. VA incidence during 24 to 48 hours of STEMI is negligibly low, thus precluding assessment of its prognostic importance.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
VALIDATE-SWEDEHEART substudy of 2886 STEMI patients; ventricular arrhythmia after PCI was associated with 6.68-fold higher mortality vs VA before PCI.
Warum dies für die Hirudotherapie relevant ist
Diese präspezifizierte Substudie der VALIDATE-SWEDEHEART-Studie analysierte den prognostischen Wert früher ventrikulärer Arrhythmien bei 2.886 Patienten mit ST-Hebungs-Myokardinfarkt, die sich einer primären PCI unterzogen, und ergab, dass VA nach PCI mit signifikant höherer Mortalität assoziiert war als VA vor PCI (HR 6,68), während frühe VA bei lebend entlassenen Patienten mit stationärer, jedoch nicht mit langfristiger Mortalität assoziiert war. Die Hauptstudie verglich Bivalirudin mit Heparin, was die einzige tangentiale Verbindung zur Familie der Hirudin-/aus Blutegeln stammenden Antikoagulanzien darstellt. Für ASH ist die Relevanz minimal: Dies ist eine kardiale Arrhythmie-Prognosestudie ohne Blutegel-bezogene Intervention, Outcome oder Hypothese. EINSCHRÄNKUNG: Diese Studie befasst sich nicht mit Blutegeln, Blutegeltherapie oder Blutegel-Sekretom; die Bivalirudin-Verbindung ist für die arrhythmie-fokussierte Analyse zufällig, und die Ergebnisse haben keine direkte Anwendung für die Hirudotherapie.
Zitation
Prognostic value of early sustained ventricular arrhythmias in ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: A substudy of VALIDATE-SWEDEHEART trial.
Demidova MM et al. · Heart Rhythm O2, 2022
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026